Clinical correlations between chronic hepatitis C infection and decreasing bone mass density after treatment with interferon-alpha
10.1016/j.apjtb.2016.11.027
- Author:
Vahid BABAEI
1
;
Shahram TEIMOURIAN
1
;
Masoud GHORBANI
2
;
Nastaran MOHSENI
3
;
Hojjat AFRAID
4
;
Yassaman SAGHAEI
4
Author Information
1. Department of Medical Genetics, Iran University of Medical Sciences
2. Department of Research and Development, Research and Production Complex, Pasteur Institute of Iran
3. Biotechnology Research Center, Biotechnology Department, Venom & Biotherapeutics Molecules Laboratory, Pasteur Institute of Iran
4. Iranian Blood Transfusion Organization
- Publication Type:Journal Article
- Keywords:
Bone mass density;
Bone mass loss;
Hepatitis C;
Interferon alpha;
Liver fibrosis
- From:Asian Pacific Journal of Tropical Biomedicine
2017;7(2):161-165
- CountryChina
- Language:Chinese
-
Abstract:
Objective To compare the bone mass density in chronic hepatitis patients before and after interferon-α treatment. Methods A total of 70 patients with chronic hepatitis C were treated with interferon-α and were evaluated. The treatment dosage was three million IU three times a week for one year. All the patients underwent bone mass density detection at lumbar spine and femoral neck before and after the interferon-α treatment. All the necessary information such as age, sex, and laboratory test, history of occurrence of fractures, lifestyle, and menopause status was collected by interviewers face-to-face from participants at the research visit. Smoking was categorized by whether participants were nonsmokers or smokers. Menopause was designated if there had been complete cessation of menses for more than 12 months. All statistical analyses were performed by SPSS version 14 (SPSS, Inc., Chicago, IL, USA). Results Among 70 patients, 52% were male, 48% were female and the mean age was (57.0 ± 9.6) years (range: 24–79). Twenty-nine percent of the patients had a history of smoking. The mean body mass index was (24.4 ± 3.6) kg/m
